Effector T-cell Levels May Predict Disease Progression, Survival
Higher levels of inflammatory immune cells called effector T-cells at the time of diagnosis are associated with faster disease progression…
Articles by Marisa Wexler, MS
Tofersen to Treat SOD1 ALS Under Review for European Union
The European Medicines Agency (EMA) has agreed to review an application seeking the approval of tofersen in treating amyotrophic…
Implantable Device That Stimulates Muscles Prevents Atrophy in Mice
A soft robotic implantable device that can exert mechanical force on muscles was shown to reduce muscle atrophy in a…
Results of Phase 3 Trial of TUDCA in Slowing ALS Likely Next Year
An ongoing Phase 3 clinical trial in Europe is testing whether tauroursodeoxycholic acid, added to standard therapy, can slow disease…
ALS Patients Given NurOwn Calling for FDA Meeting to Discuss Refusal
People who took part in clinical testing of NurOwn, a cell therapy for amyotrophic lateral sclerosis (ALS), and family members…
Study Reveals How Growing Motor Neurons Guide Blood Vessel Growth
An international team of researchers discovered how, during development, motor neurons — the nerve cells controlling movement whose death causes…
PARADIGM Trial for PrimeC Set to Enroll Soon in US, Italy
NeuroSense Therapeutics has received the go-ahead to begin enrolling patients in the U.S. and Italy for a Phase 2b…
FDA Declines to Consider Approving NurOwn to Treat ALS
The U.S. Food and Drug Administration (FDA) notified Brainstorm Cell Therapeutics that it will not accept for review a company…
Verge Starts First-in-human Trial of Its Novel PIKfyve Inhibitor for ALS
Four years after its discovery via an artificial intelligence (AI) platform, Verge Genomics will test its amyotrophic lateral…
New Study Uncovers Mechanism of CuATSM, ALS Therapy Now in Trials
CuATSM, a potential amyotrophic lateral sclerosis (ALS) therapy that’s now in clinical trials, may work by altering how certain…